Lancashire and South Cumbria
Formulary
Formulary
13 Skin
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
13-05-02 Preparations for psoriasis
| Dimethyl Fumarate Skilarence® |
|
Formulary
|
Tablets 30mg, 120mg |
 NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
|
| Ixekizumab Taltz® |
|
Formulary
|
80mg/1mL pre-filled pen |
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update July 2021: Oral retinoid medicines (isotretinoin, alitretinoin, and acitretin): temporary monitoring advice during coronavirus (COVID-19) pandemic
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
- MHRA: Oral retinoids pregnancy prevention
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG153: Psoriasis: assessment and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
- NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
- NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA701: Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)
- NICE TA718: Ixekizumab for treating axial spondyloarthritis
- UKMI Q &A: acitretin use in renal impairment/ renal replacement therapies
UKMI Q&A: Fumaderm - What is the evidence in psoriasis